NEW YORK (GenomeWeb News) – Curie-Cancer today announced two three-year partnerships between Institute Curie and French biotech firm Meiogenix to further develop that firm's meiotic recombination technology.

Under the terms of the deals, the technology called SpiX, short for Spo11-based technology, will be used in yeast and mice "to exploit the unexplored natural biodiversity of organisms."

Financial and other terms of the deals were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.